Related Experiment Video
Updated: Jun 17, 2026
Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors
Published on: July 17, 2020
Targeting Pyk2 for therapeutic intervention
Christopher A Lipinski1, Joseph C Loftus
1Mayo Clinic Collaborative Research Building, Department of Biochemistry and Molecular Biology, Scottsdale, AZ 85259, USA.
Importance Of The Field:
The focal adhesion tyrosine kinases FAK and Pyk2 are uniquely situated to act as critical mediators for the activation of signaling pathways that regulate cell migration, proliferation and survival. By coordinating adhesion and cytoskeletal dynamics with survival and growth signaling, FAK and Pyk2 represent molecular therapeutic targets in cancer as malignant cells often exhibit defects in these processes.
Areas Covered In This Review:
This review examines the structure and function of the focal adhesion kinase Pyk2 and intends to provide a rationale for the employment of modulating strategies that include both catalytic and extra-catalytic approaches that have been developed in the last 3 - 5 years.
What The Reader Will Gain:
Targeting tyrosine kinases in oncology has focused on the ATP binding pocket as means to inhibit catalytic activity and downregulate pathways involved in tumor invasion. This review discusses the available catalytic inhibitors and compares them to the alternative approach of targeting protein-protein interactions that regulate kinase activity.
Take Home Message:
Development of specific catalytic inhibitors of the focal adhesion kinases has improved but significant challenges remain. Thus, approaches that inhibit the effector function of Pyk2 by targeting regulatory modules can increase specificity and will be a welcome asset to the therapeutic arena.
Insights
Targeting focal adhesion kinase Pyk2 offers new cancer therapies. Strategies modulating Pyk2, including catalytic and extra-catalytic approaches, are crucial for inhibiting tumor invasion and improving patient outcomes.
Area of Science:
- Molecular biology
- Oncology
- Biochemistry
Background:
- Focal adhesion kinases (FAKs), FAK and Pyk2, are key regulators of cell migration, proliferation, and survival.
- Dysregulation of FAK and Pyk2 signaling is implicated in cancer pathogenesis, making them critical therapeutic targets.
- These kinases link cell adhesion and cytoskeletal dynamics with crucial survival and growth pathways.
Purpose of the Study:
- To review the structure and function of the focal adhesion kinase Pyk2.
- To provide a rationale for therapeutic strategies targeting Pyk2.
- To discuss recent (3-5 years) catalytic and extra-catalytic approaches for Pyk2 modulation.
Main Methods:
- Review of existing literature on Pyk2 structure, function, and therapeutic targeting.
- Analysis of catalytic inhibition strategies targeting the ATP binding pocket.
- Exploration of extra-catalytic approaches, including targeting protein-protein interactions.
Main Results:
- Current oncology strategies primarily target the ATP binding pocket of tyrosine kinases.
- This review compares established catalytic inhibitors with emerging protein-protein interaction targeting methods.
- Development of specific Pyk2 catalytic inhibitors has progressed, but challenges persist.
Conclusions:
- Targeting Pyk2's effector function through regulatory modules offers increased specificity.
- Extra-catalytic approaches represent a promising avenue for novel cancer therapeutics.
- Inhibiting Pyk2's function through novel strategies can enhance specificity and therapeutic efficacy in oncology.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include: